An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM)

American Journal of Hematology

Volumn 91, Issue 8, 2016, Pages 806-811

  Leleu, Xavier ^a   Terpos, Evangelos ^b   Sanz, Ramón García ^c   Cooney, Julian ^d   O'Gorman, Peter ^e   Minarik, Jiri ^f   Greil, Richard ^g   Williams, Catherine ^h   Gray, Diep ⁱ   Szabo, Zsolt ^j  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^f PALACKÝ UNIVERSITY   (Czech Republic)

^g PARACELSUS MEDICAL UNIVERSITY   (Austria)

^h NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

ⁱ Consultant Biostatistician ^*  (United Kingdom)

^j AMGEN INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; FILGRASTIM; LENALIDOMIDE; PEGFILGRASTIM;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; DRUG DOSE REDUCTION; DRUG EXPOSURE; FEBRILE NEUTROPENIA; FEMALE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; OBSERVATIONAL STUDY; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; VERY ELDERLY;

EID: 84978271694     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24416     Document Type: Article

References (27)

1. Agarwal A, Mahadevan D. Novel targeted therapies and combinations for the treatment of multiple myeloma. Cardiovasc Hematol Disord Drug Targets 2013;13:2–15.
2. Dimopoulos MA, Richardson PG, Moreau P, et al. Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol 2015;12:42–54.
3. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–2520.
4. Richardson PG, Laubach J, Mitsiades CS, et al. Managing multiple myeloma: The emerging role of novel therapies and adapting combination treatment for higher risk settings. Br J Haematol 2011;154:765–762.
5. Dimopoulos MA, Palumbo A, Attal M, et al. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: Consensus statement. Leukemia 2011;25:749–760.
6. Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 2014;371:906–917.
7. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015;372:142–152.
8. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123–2132.
9. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133–2142.
10. Richardson P, Jagannath S, Hussein M, et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009;114:772–778.
11. Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: A randomized phase 2 study. Blood 2014;123:1826–1832.
12. Fiegl M, Steger GG, Studnicka M, et al. Pegfilgrastim prophylaxis in patients at different levels of risk for chemotherapy-associated febrile neutropenia: An observational study. Curr Med Res Opin 2013;29:505–515.
13. Jolis L, Carabantes F, Pernas S, et al. Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: A prospective, observational study. Eur J Cancer Care (Engl) 2013;22:513–521.
14. Krzemieniecki K, Sevelda P, Erdkamp F, et al. Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy–findings from clinical practice. Support Care Cancer 2014;22:667–677.
15. Pettengell R, Johnsen HE, Lugtenburg PJ, et al. Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma. Support Care Cancer 2012;20:647–652.
16. Pettengell R, Schwenkglenks M, Leonard R. Neutropenia occurrence and predictors of reduced chemotherapy delivery: Results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 2008;16:1299–1309.
17. Salar A, Haioun C, Rossi FG, et al. The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: Findings from clinical practice. Leuk Res 2012;36:548–553.
18. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:3–9.
19. Knop S, Gerecke C, Liebisch P, Topp MS, et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: A report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 2009;113:4137–4143.
20. Revlimid® Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000717/WC500056018.pdf. Accessed 16 January 2015.
21. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106:4050–4053.
22. Schwamborn K, Gorschluter M, Glasmacher A, et al. Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma. Ger Med Sci 2011;9:Doc26.
23. Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Crit Rev Oncol Hematol 2014;90:190–199.
24. Palumbo A, Blade J, Boccadoro M, et al. How to manage neutropenia in multiple myeloma. Clin Lymphoma Myeloma Leuk 2012;12:5–11.
25. Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011;47:8–32.
26. Mateos MV, Garcia-Sanz R, Colado E, et al. Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy? Br J Haematol 2008;140:324–326.
27. Sun HL, Atenafu EG, Yeboah E, et al. Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leuk Lymph 2015;56:407–414.